Canadian Treat and Extend Analysis Trial With Ranibizumab
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CAN-TREAT
- Sponsors Novartis
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2015 Planned End Date changed from 1 May 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 06 Nov 2015 Planned primary completion date changed from 1 May 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.